Compass Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. The company's lead product candidate includes CTX-471. Compass Therapeutics Inc. is based in Boston, MA.
Compass Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
299.38M
Enterprise Value
255.90M
Enterprise Value/EBITDA(ttm)
-4.53
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
3.06
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
25.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-384.59%
Return on Equity(ttm)
-32.37%
Return on Invested Capital(ttm)
-35.39%
Return on Assets(ttm)
-30.67%
Income Statement
Revenue(ttm)
850.00K
Revenue Per Share(ttm)
0.01
Gross Profit(ttm)
850.00K
EBITDA(ttm)3
-56.52M
Net Income Available to Common(ttm)
-49.38M
Diluted EPS(ttm)
-0.37
Share Statistics
Beta (5Y Monthly)
1.17
52-Week Change
13.38%
S&P 500 52-Week Change
7.42%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
138.28M
Dividend Yield
0.00%
Float4
98.38M
% Held by Insiders
28.50%
% Held by Institutions
68.43%
Balance Sheet
Total Cash(mrq)
126.72M
Total Cash Per Share(mrq)
0.92
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
14.96%
Quick Ratio(mrq)
31.84%
Book Value Per Share(mrq)
0.91
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.33
Free Cash Flow(ytd)
-44.90M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.